EX-10.24 28 d293184dex1024.htm EX-10.24 CONFIDENTIAL CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. […***…] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED...Platform Technology Transfer and License Agreement • May 5th, 2020 • Delaware
Contract Type FiledMay 5th, 2020 JurisdictionTHIS PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (the “Agreement”), effective as of 21 April, 2016 (the “Effective Date”), by and between GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, a corporation organized and existing under the laws of England and Wales, with its registered office located at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“GSK”) and ZYMEWORKS INC., a corporation organized and existing under the laws of Canada, and extraprovincially in British Columbia, having an address at 540-1385 West 8th Avenue, Vancouver, BC, Canada V6H 3V9 (“Zymeworks”). Zymeworks and GSK are each referred to individually as a “Party” and together as the “Parties”.
ContractPlatform Technology Transfer and License Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionCONFIDENTIAL [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
AMENDMENT NO. 2 TO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENTPlatform Technology Transfer and License Agreement • May 8th, 2019 • Codexis Inc • Industrial organic chemicals
Contract Type FiledMay 8th, 2019 Company IndustryThis AMENDMENT NO. 2 TO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (“Amendment No. 2”) is effective as of January 1, 2019 (the “Amendment No. 2 Effective Date”) by and between CODEXIS, INC., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, CA 94063 (“CODEXIS”) and MERCK SHARP AND DOHME CORP., having a place of business at One Merck Drive, Whitehouse Station, NJ 08889-0100. (“MERCK”).
AMENDMENT NO. 1 TO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENTPlatform Technology Transfer and License Agreement • March 1st, 2019 • Codexis Inc • Industrial organic chemicals
Contract Type FiledMarch 1st, 2019 Company IndustryAMENDMENT NO. 1 TO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT effective as of October 10, 2018 (the EFFECTIVE DATE) (this “Amendment”) by and between CODEXIS, INC., (the “Vendor”), a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, CA 94063 (“CODEXIS”) and MERCK SHARP AND DOHME CORP. (the “Company”), having a place of business at One Merck Drive, Whitehouse Station, NJ 08889-0100. (“MERCK”)
PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENTPlatform Technology Transfer and License Agreement • August 6th, 2019 • Codexis, Inc. • Industrial organic chemicals • New York
Contract Type FiledAugust 6th, 2019 Company Industry JurisdictionTHIS PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of 2 May 2019 (the “Effective Date”), by and between Codexis, Inc., a corporation organized and existing under the laws of Delaware (“Codexis”), and Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland (“Novartis”). Codexis and Novartis are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENTPlatform Technology Transfer and License Agreement • May 17th, 2019 • Zymeworks Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 17th, 2019 Company Industry JurisdictionThis First Amendment (the “Amendment”) to that certain Platform Technology Transfer and License Agreement, dated April 21, 2016 (the “Agreement”) by and between GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, a corporation organized and existing under the laws of England and Wales, with its registered office located at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“GSK”) and ZYMEWORKS INC., a corporation organized and existing under the laws of British Columbia, having an address at 540-1385 West 8th Avenue, Vancouver, BC, Canada V6H 3V9 (“Zymeworks”), is entered into as of May 14, 2019 (the “First Amendment Effective Date”). Zymeworks and GSK are each referred to individually as a “Party” and together as the “Parties.”
PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENTPlatform Technology Transfer and License Agreement • February 28th, 2022 • Codexis, Inc. • Industrial organic chemicals • New York
Contract Type FiledFebruary 28th, 2022 Company Industry JurisdictionTHIS PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of August 3, 2015 (the “Effective Date”), by and between Codexis, Inc., a corporation organized and existing under the laws of Delaware (“Codexis”), and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“Merck”). Codexis and Merck are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”